Physician profile
Richard Valido
NPI 1083673073
$1,382.64
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.08 · 2020: $115 · 2021: $292 · 2022: $446 · 2023: $444 · 2024: $30.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.72 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Pfizer INC. | $202.46 | 2019-2024 | |
| Gynesonics, INC. | $105.24 | 2022 | |
| Sumitomo Pharma America, INC. | $94.55 | 2023 | Myfembree |
| Exeltis, USA INC. | $88.72 | 2021-2024 | Slynd |
| Therapeuticsmd, INC. | $82.19 | 2021-2022 | |
| Exact Sciences Corporation | $64.86 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $64.46 | 2021-2023 | Veozah, Myrbetriq |
| Avion Pharmaceuticals | $60.51 | 2020-2023 | Balcoltra |
| Channel Medsystems, INC. | $50.90 | 2022 | |
| Merck Sharp & Dohme LLC | $37.94 | 2023 | Gardasil 9 |
| Evofem Biosciences, INC. | $33.99 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $28.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.50 | 2023 | Xifaxan |
| Shield Therapeutics INC | $18.18 | 2023 | Accrufer |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $17.88 | 2023 | |
| Phathom Pharmaceuticals, INC. | $16.18 | 2023 | Voquezna |
| Scynexis, INC. | $14.54 | 2022 | |
| Hologic Sales and Service, LLC | $13.98 | 2020 | |
| Minerva Surgical, INC | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Valido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.